Bears Don't Think Celldex Therapeutics, Inc. (CLDX) is Done Falling

Celldex Therapeutics, Inc. (CLDX) is yet another biotech victim

by Josh Selway

Published on Apr 27, 2015 at 3:22 PM

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is following the rest of the biotech sector lower today, dropping 13% to trade at $26.17. In fact, the equity has been placed on the short-sale restricted list. Traders have gone to the options pits to place bearish bets, with puts crossing at three times the normal intraday pace. It appears buy-to-open activity is taking place at the May 24 put. This means traders expect CLDX to fall at least another 8.3% before front-month options expire at the close on Friday, May 15.

Put buying was popular on CLDX even before today, though. The equity's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.63 is only 2 percentage points from an annual bearish extreme. This means puts have been bought to open over calls at a faster-than-usual pace during the past 10 weeks.

However, analysts have a completely different take on the shares. All eight brokerage firms with coverage on the stock rate it a "strong buy."

It's rare to see Celldex Therapeutics, Inc. (NASDAQ:CLDX) struggling like this. The shares have more than doubled in the past 12 months, and have outpaced the broader S&P 500 Index (SPX) by nearly 31 percentage points during the past three months. As such, it's possible some of the recent put buying could be a result of shareholders protecting paper profits against any unexpected pullbacks.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.
Stocks Surge During Holiday-Shortened Week
Stocks chugged higher as the government responded to the coronavirus crisis with more funding
Bank Stocks Ease Investors Back Into Earnings Season
Bank stocks will kick off earnings season next week
The Top Lithium Play of 2020
Click to continue to advertiser's site.